Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Stock
NASDAQ · ELDN
2.62
Fundamentals
Market cap
$212.90M
Price / Earnings ratio
-2.2x
Price / Sales ratio
N/A
Price / Book ratio
6.5x
Return on assets
-0.5%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
SectorHealthcare
IndustryBiotechnology
Employees33
CEODr. David-Alexandre C. Gros M.D., Ph.D.
IPO DateSep 17, 2014
HeadquartersIrvine, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director | 1972 |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director | 1966 |
| Mr. Paul Sean Little | Chief Financial Officer | 1965 |
| Mr. John Herberger | Vice President of Technical Operations | — |
| Mr. Bryan E. Smith J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1980 |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer | — |
| Ms. Marina Escudero | VP & Head of Clinical Operations | — |
| Dr. Sepideh Habibi | VP and Head of Safety & Pharmacovigilance | — |
Fundamentals
Valuation
Market cap$212.90M
Price-to-sales ratioN/A
Price-to-book value6.52
Price-earnings ratio-2.20
Return on Equity-150.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.91
Income Statement
Average volume925,740
EBITDA$-79.14M
1 year high (52w)$4.60
1 year low (52w)$1.35
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



